Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Bone Marrow Transplant ; 59(2): 232-238, 2024 02.
Article in English | MEDLINE | ID: mdl-38007531

ABSTRACT

Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.


Subject(s)
Artificial Intelligence , Hematopoietic Stem Cell Transplantation , Humans , Adult , Transplantation, Homologous , Neoplasm Recurrence, Local , Hematopoietic Stem Cell Transplantation/methods , Prognosis , Chronic Disease , Retrospective Studies
2.
Hematol Oncol Stem Cell Ther ; 13(1): 7-16, 2020 03.
Article in English | MEDLINE | ID: mdl-31449781

ABSTRACT

The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. While this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state of the art treatments including transplantation, by providing financial, technological, legal, ethical and other needed support. This would prove beneficial in providing successful programs customized to the needs of their population, and potentially provide long-term cost-savings by circumventing the need for their citizens to seek care abroad. Costs of establishing HSCT program and the costs of the HSCT procedure itself can be substantial barriers in developing countries. Additionally, socioeconomic factors intrinsic to specific countries can influence access to HSCT, patient eligibility for HSCT and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting.


Subject(s)
Bone Marrow Transplantation/methods , Developing Countries/statistics & numerical data , Hematopoietic Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Humans , Socioeconomic Factors
3.
J Intern Med ; 285(4): 407-418, 2019 04.
Article in English | MEDLINE | ID: mdl-30372796

ABSTRACT

BACKGROUND: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES: To assess the incremental improvement of transplanted AML patients in the last two decades. METHODS: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993-2002, 2003-2007 and 2008-2012). RESULTS: The analysis comprised a total of 20 187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993-2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77-0.92; P = 0.003], a benefit which also extended to improved overall survival (OS; HR = 0.8, CI 95%, 0.73-0.89; P < 0.0001), and decreased nonrelapse mortality (NRM) rates (HR = 0.65, CI 95%, 0.56-0.75; P < 0.0001). Subset analysis revealed that in MSD, the rates of LFS, NRM and OS significantly improved in patients in the more recent cohort with similar results also seen in MUD. Finally, the incidence of acute graft-versus-host disease (GVHD) was significantly reduced leading to improved GVHD-free/relapse-free survival (GRFS) rates in more recently transplanted patients. CONCLUSION: Outcome of allo-SCT for AML patients has markedly improved in the last two decades owing to decreased nonrelapse mortality and improved rates of leukaemia-free survival resulting in significantly longer survival.


Subject(s)
Leukemia, Myeloid, Acute/therapy , Stem Cell Transplantation/methods , Adolescent , Adult , Aged , Disease-Free Survival , Female , Humans , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Transplantation, Homologous/methods , Treatment Outcome , Young Adult
4.
Leukemia ; 30(2): 447-55, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26293645

ABSTRACT

Haploidentical hematopoietic stem cell transplants (HSCTs) are increasingly used, but it is unknown whether they have a stronger graft-versus-leukemia (GVL) effect. We analyzed 10 679 acute leukemia patients who underwent HSCT from an HLA-matched sibling donor (MSD, n=9815) or a haploidentical donor (⩾2 HLA-antigen disparity, n=864) between 2007 and 2012, reported to the European Group for Blood and Marrow Transplantation. In a Cox regression model, acute and chronic graft-versus-host disease (GVHD) was added as time-dependent variables. There was no difference in probability of relapse between recipients of haploidentical and MSD grafts. Factors of importance for relapse after T-cell-replete grafts included remission status at HSCT, Karnofsky score ⩽80, acute GVHD of grade II or higher and chronic GVHD (P<10(-5)). Patients with post-transplant cyclophosphamide (n=194) had similar outcome as other T-cell-replete haploidentical transplants (n=369). Non-relapse mortality was significantly higher in the haploidentical group compared with that in MSD patients (P<10(-5)). Leukemia-free survival was superior in the MSD patients receiving T-cell-replete (P<10(-5)) or T-cell-depleted grafts (P=0.0006). The risk of relapse was the same in acute leukemia patients who received haploidentical donor grafts as in those given MSD transplants, suggesting a similar GVL effect.


Subject(s)
Graft vs Leukemia Effect , Haplotypes , Histocompatibility Testing , Leukemia/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Hematopoietic Stem Cell Transplantation , Humans , Infant , Leukemia/mortality , Middle Aged , Proportional Hazards Models , Recurrence
5.
Bone Marrow Transplant ; 49(9): 1170-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24978140

ABSTRACT

This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 resulted in a longer time to neutrophil engraftment (17 vs 15 days, P < 0.0001) but no difference in incidence of grade II-IV acute (P = 0.54) or chronic GVHD (P = 0.51). In patients < 50 years of age, FB2 was associated with a higher 2-year cumulative incidence of relapse (33 ± 6% vs 20 ± 4%, P = 0.04), but there was no difference in 2-year leukemia-free survival (LFS) (P = 0.45), OS (P = 0.53) or non-relapse mortality (P = 0.17). In recipients ⩾ 50 years of age, FB2 resulted in better 2-year LFS (63 ± 4% vs 42 ± 7%, P = 0.02) and OS (68 ± 4% vs 45 ± 7%, P = 0.006); a lower 2-year non-relapse mortality, albeit not statistically significant (15 ± 3% vs 29 ± 6%, P = 0.06), was observed with FB2. FB2 is an effective and well-tolerated regimen in patients ⩾ 50 years of age and does not compromise survival when used in patients <50 years undergoing allogeneic transplantation for AML in first CR.


Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Busulfan/administration & dosage , Hematopoietic Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Administration, Intravenous , Adult , Aged , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous , Young Adult
6.
Bone Marrow Transplant ; 48(6): 761-70, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23208314

ABSTRACT

In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who underwent transplantation with an HLA-identical sibling donor between 1998 and 2004 were analyzed according to four regimens of conditioning intensity: reduced-intensity conditioning (RIC) (either intermediate RIC (IntermRIC) or non-myeloablative (NMA) RIC), and myeloablative conditioning (MC) in 718 patients (either conventional MC or hyperintense MC. In multivariate cox analysis, patients undergoing NMA transplantation had lower non-relapse mortality risk in the first 100 days after transplantation (P<0.01), but a higher risk beyond day +100 (P=0.02), as well as higher relapse incidence in the first 12 months (P<0.01), but the risk was similar in all groups beyond 12 months. The probabilities of PFS and OS up to 7 years were significantly lower only in the NMA subgroup (P0.01 for both). The 7-year OS was 53%, 29%, 56% and 51%, respectively. Our data suggest that prospective studies comparing RIC regimens (especially IntermRIC) with MC are appropriate in patients with AML and RAEB who are in a non-advanced disease status.


Subject(s)
Anemia, Refractory, with Excess of Blasts/therapy , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/therapy , Siblings , Tissue Donors , Transplantation Conditioning/methods , Adolescent , Adult , Aged , Allografts , Anemia, Refractory, with Excess of Blasts/mortality , Disease-Free Survival , Female , Follow-Up Studies , Humans , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Risk Factors , Survival Rate
7.
Hematol Oncol Stem Cell Ther ; 4(4): 161-6, 2011.
Article in English | MEDLINE | ID: mdl-22198187

ABSTRACT

BACKGROUND AND OBJECTIVES: In Algeria, the incidence of hematologic malignancies has been difficult to estimate for many years. Today, many hematological centers, including 14 university hospitals, have been developed in the entire north and have useful epidemiological data pertinent to acute myeloid leukemia (AML). We studied the incidence of AML and its subtypes, age distribution, geographic distribution and trends in the rate of diagnosis over the last 5 years in Algeria. Secondary goals were to study trends of referral of AML cases from various regions to specific centers to assess the needs for health infrastructure and change of current practices. DESIGN AND SETTING: Retrospective analysis of nationwide survey of all adult cases of AML (>16 years) diagnosed between 1 January 2006 and 31 December 2010. PATIENTS AND METHODS: A survey form was distributed to all departments of hematology at the 15 participating centers. RESULTS: The 1426 cases of AML diagnosed during the study period represented an annual incidence of 0.91/100000 persons with a male to female (M/F) ratio of 1:16 and a median age of 45 years (range, 16-82 years). Nationally, 20% of cases AML were diagnosed in the whole western region of the country, 47% in the central and 33% in the east. There was a trend of continuous increase in the rate with age and in the rate of diagnosis over the last 5 years. The most common subtype was M2, followed by M4 and M5. CONCLUSION: An overall increase in the number of AML patients diagnosed nationwide over the last five years indicates a need for additional health care resources including curative and therapy-intense strategies, such as stem cell transplant facilities to optimize outcome. The relatively younger age of patients compared to the Western countries may be due to the demographic composition of our population.


Subject(s)
Leukemia, Myeloid, Acute/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Algeria/epidemiology , Female , Humans , Incidence , Leukemia, Myeloid, Acute/diagnosis , Male , Middle Aged , Retrospective Studies , Young Adult
8.
Rev Med Interne ; 26(10): 777-83, 2005 Oct.
Article in French | MEDLINE | ID: mdl-16203055

ABSTRACT

UNLABELLED: The association of myelodysplastic syndromes (MDS) with auto-immune diseases and humoral disorders have already been reported. In this prospective study we tried to estimate type and the frequency of immunological associated diseases among patients affected by MDS. PATIENTS-METHODS: In this prospective study, auto-immune disease and humoral immunity disorders were systematically searched during MDS and conversely MDS searched during cytopenia. All MDS secondary to chemotherapy and the children's MDS were excluded. The MDS diagnosis was established according to FAB criteria and patients were classified in two groups A or B according to presence (group A) or not (group B) of dysimmune manifestations. RESULTS: Forty patients(19 males and 21 females, mean age of 56,6 years) with MDS have been enrolled during this period (group A: 20 patients). Associated diseases are following: systemic lupus erythematosus (three), lupus-like syndrome(one), sarcoidisis(one), Sjogrën syndrome(one), polyarthritis (two), chronic liver diseases (three), autoimmune thyroid diseases (two), pyoderma gangrenosum (one), Crohn's disease(one), haemolytic anaemia (one), and pericardial effusion(one). CONCLUSION: A wide spectrum of auto-immune manifestations is frequently reported in myelodysplastic syndromes. Further studies are necessary for discuss the current physiopathological hypothesis with their therapeutic relevance.


Subject(s)
Autoimmune Diseases/complications , Myelodysplastic Syndromes/immunology , Adult , Aged , Aged, 80 and over , Anemia, Hemolytic/complications , Arthritis/complications , Chronic Disease , Crohn Disease/complications , Female , Humans , Liver Diseases/complications , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/mortality , Pericardial Effusion/complications , Prospective Studies , Pyoderma Gangrenosum/complications , Sarcoidosis/complications , Sjogren's Syndrome/complications , Thyroid Diseases/complications
9.
Blood Coagul Fibrinolysis ; 6(6): 549-52, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7578897

ABSTRACT

Severe hypofibrinogenemia was found in an Algerian woman who, since the age of 37 years, suffered three different episodes of ischemic necrosis of the toes and fingers leading to amputation of the toes and surgical removal of necrotic tissue (necretomy). No anti-fibrinogen antibody was present. The deficiency appeared to be due to severe congenital hypofibrinogenemia since the fibrinogen level remained at the same low level over a long period, without any abnormality of other coagulation proteins. The thrombotic events may be explained by the increased thrombin generation observed in the patient's plasma, due to the lack of thrombin adsorption onto a fibrin net.


Subject(s)
Afibrinogenemia/complications , Fingers/blood supply , Ischemia/etiology , Toes/blood supply , Adult , Afibrinogenemia/blood , Algeria , Amputation, Surgical , Blood Coagulation Factors/metabolism , Female , Fingers/pathology , Fingers/surgery , Humans , Necrosis , Partial Thromboplastin Time , Prothrombin Time , Thrombin/metabolism , Thrombin Time , Toes/pathology , Toes/surgery
10.
Bull Cancer ; 80(1): 50-4, 1993 Jan.
Article in French | MEDLINE | ID: mdl-8204918

ABSTRACT

Cisplatinum is highly effective in numerous solid tumors and was evaluated in Hodgkin's disease clinical stages (CS) I/II. Sixty-five patients (43 male, 22 female; median age 25, with 12 patients under 16: CS IA-IIA 41, IB 5, IIB 19) were randomly assigned to one of the following arms (PAF87 protocol): 3 ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine with methylprednisolone) cycles (ABVD arm) or 3 ABVD plus cisplatinum cycles (ABVD-Plt arm) followed by radiotherapy (RT); extended field (40 Gy) RT with a short paraaortic field including the spleen (30 Gy) was then administered in the ABVD arm; extended field (30 Gy) without lombosplenic port prophylaxis. RT was administered in ABVD-Plt arm when patients were in complete remission (CR) after chemotherapy (CT). Median follow-up was 35 months (6-62 months). During CT, 1 patient (ABVD-Plt) died from viral meningo-encephalitis; five patients (1 ABVD, 4 ABVD-Plt) stopped treatment because of emesis, of whom three receiving only 1.5-2.5 (ABVD-Plt) cycles, are still in CR after 13-60 months. Fifty-five patients (27 ABVD-Plt) were in CR after CT. Among the 27 ABVD-Plt patients, all in CR after RT, two died (one from myocardial infarction and one from immunoblastic lymphoma); one patient from the ABVD arm died from gastro-intestinal hemorrhage in 1st CR. No ABVD-Plt patient relapsed; 1 ABVD patient relapsed in non-irradiated area. At five years, actuarial survival/relapse-free survival was 96.1/90% and 88.2/100% for ABVD and ABVD-Plt patients, respectively.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/therapeutic use , Hodgkin Disease/therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemotherapy, Adjuvant , Child , Child, Preschool , Cisplatin/adverse effects , Combined Modality Therapy , Drug Evaluation , Female , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Humans , Male , Methylprednisolone/therapeutic use , Middle Aged , Neoplasm Staging , Time Factors
11.
Sem Hop ; 53(16): 885-9, 1977 Apr 23.
Article in French | MEDLINE | ID: mdl-197607

ABSTRACT

These first cases of hemoglobinosis H show that alpha-thalassemia is not a simple curiosity in this part of the Western Mediterranean. They are not localised to a single part of Algeria as the areas from which the patients came were more than 150 km apart. They suggest that the enquiry should be continued by other means to determine the prevalence and pathological incidence.


Subject(s)
Hemoglobin H , Hemoglobins, Abnormal , Thalassemia/epidemiology , Adolescent , Adult , Algeria , Child , Child, Preschool , Female , Hemoglobin H/analysis , Hemoglobins, Abnormal/analysis , Humans , Male , Thalassemia/blood , Thalassemia/genetics
12.
Sem Hop ; 53(16): 911-5, 1977 Apr 23.
Article in French | MEDLINE | ID: mdl-197612

ABSTRACT

The clinical, hematological and therapeutic aspects of 36 cases of acute myeloblastic leukemia in children and 98 cases in adults observed in Algeria are discussed. In Algeria, acute myeloblastic leukemia is more frequent in children than in other populations. In our series there was a very unusual female predominance. Clinically, we observed in children only, 8 cases of chloroma of the orbit. From the hematological point of view, the only difference was a higher incidence of leukopenia and hyperleukocytosis after the age 30 years. The results of VAMP treatment (vincristin, amethopterin, 6-mercaptopurine, and prednisone) are better in children than in adults. But analysis of the results is more interesting if one places the patients in age groups of ten years. The percentage of complete remissions is maximum in the age group 0 to 10years and then falls regularly.


Subject(s)
Leukemia, Myeloid, Acute , Adolescent , Adult , Age Factors , Child , Child, Preschool , Female , Humans , Infant , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/drug therapy , Male , Middle Aged , Remission, Spontaneous
SELECTION OF CITATIONS
SEARCH DETAIL
...